Most Read Articles
01 Oct 2013

Heart disease is still New Zealand’s biggest killer, with one Kiwi dying from coronary heart disease every 90 minutes. Pharmacy Today New Zealand looks at how pharmacists can help

Dr. James Salisi, 01 Jul 2014

The recent spike in the number of new cases of human immunodeficiency virus (HIV) infection in the Philippines means that clinicians and pharmacists alike may need to increase their awareness and competency in prescribing and monitoring HIV treatment. Although taught in medical and pharmacy schools, the scarcity in exposure to clinical cases before highlights the need to for physicians and pharmacist to review HIV pharmacotherapy in order to cater to the increasing HIV patient population.

3 days ago
A recent study suggests that discontinuation of dexamethasone premedication after two uneventful infusions or reduction in the dose of dexamethasone paclitaxel premedication are both safe alternatives to high-dose steroid premedications recommended in product labelling.
01 Sep 2017
Complementary medicines can play an important part in maintaining wellness, preventing deficiencies and optimizing health outcomes, says Dr Lesley Braun PhD, Director of the Blackmores Institute. 

Tofacitinib shows therapeutic potential in ankylosing spondylitis

08 Feb 2017

Twice-daily tofacitinib 5 and 10 mg may produce greater improvements in signs, symptoms and objective endpoints of active ankylosing spondylitis (AS) in adults compared with placebo, according to data from a phase II study.

In addition, the drug has showed a 12-week safety profile that is similar to that reported in other indications.

A total of 207 patients were randomly assigned to one of the following treatment arms: tofacitinib 2 mg (n=52; mean age 41.8 years; 65.4 percent male), 5 mg (n=52; mean age 41.2 years; 75 percent male), 10 mg (n=52; mean age 41.6 years; 73.1 percent male) and placebo (n=51; mean age 41.9 years; 62.7 percent male). Treatment was given for 12 weeks, with a 4-week washout period.

The Assessment of SpondyloArthritis International Society 20 percent improvement (ASAS20) response rate at week 12 was used as the primary efficacy endpoint. Secondary endpoints were objective measures of disease activity, patient-reported outcomes and MRI of sacroiliac joints and spine. Safety was also assessed.

In an Emax model, ASAS20 response rate was 67.4 percent in the 10 mg arm, 63 percent in the 5 mg arm, 56 percent in the 2 mg arm, and 40.1 percent in the placebo arm.

Supportive normal approximation analysis found that the ASAS20 response rate with tofacitinib 5 mg was significantly higher than with placebo (80.8 vs 41.2 percent; p<0.001). Response rates were also greater with tofacitinib 2 and 10 mg, although the differences were not significant (51.9 and 55.8 percent, respectively).

There were general improvements observed in the secondary endpoints in the tofacitinib 5 and 10 mg arms vs placebo. Objective endpoints, including MRI, particularly showed clear dose response.

In terms of safety, adverse events showed no significant intergroup differences, without any unexpected safety findings.

Changes seen in dose-dependent laboratory outcomes returned close to baseline by week 16.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Oct 2013

Heart disease is still New Zealand’s biggest killer, with one Kiwi dying from coronary heart disease every 90 minutes. Pharmacy Today New Zealand looks at how pharmacists can help

Dr. James Salisi, 01 Jul 2014

The recent spike in the number of new cases of human immunodeficiency virus (HIV) infection in the Philippines means that clinicians and pharmacists alike may need to increase their awareness and competency in prescribing and monitoring HIV treatment. Although taught in medical and pharmacy schools, the scarcity in exposure to clinical cases before highlights the need to for physicians and pharmacist to review HIV pharmacotherapy in order to cater to the increasing HIV patient population.

3 days ago
A recent study suggests that discontinuation of dexamethasone premedication after two uneventful infusions or reduction in the dose of dexamethasone paclitaxel premedication are both safe alternatives to high-dose steroid premedications recommended in product labelling.
01 Sep 2017
Complementary medicines can play an important part in maintaining wellness, preventing deficiencies and optimizing health outcomes, says Dr Lesley Braun PhD, Director of the Blackmores Institute.